Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms.

Autor:	Serrano AG; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rocha P; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Freitas Lima C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stewart A; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang B; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Diao L; Department of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fujimoto J; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cardnell RJ; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lu W; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khan K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sable B; Amgen Inc., Thousand Oaks, CA, USA., Ellison AR; Amgen Inc., Thousand Oaks, CA, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Concannon KF; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Halperin DM; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bogdan C; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sircar K; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang M; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cargill K; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang Q; Department of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Aparicio A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lazar A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hernandez S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Estrella J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ramalingam P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., El-Naggar A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kalhor N; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gay CM; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Byers LA; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. lbyers@mdanderson.org., Solis Soto LM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. lmsolis@mdanderson.org.
Jazyk:	angličtina
Zdroj:	NPJ precision oncology [NPJ Precis Oncol] 2024 Nov 19; Vol. 8 (1), pp. 268. Date of Electronic Publication: 2024 Nov 19.
DOI:	10.1038/s41698-024-00739-y
Abstrakt:	Delta-like Ligand 3 (DLL3) targeting therapies are promising in small cell lung cancer (SCLC) treatment. However, DLL3 expression in SCLC and other neuroendocrine neoplasms (NEN) is heterogeneous and not well characterized. We describe the landscape of DLL3 at the mRNA and protein levels across SCLC, large cell neuroendocrine carcinoma (LCNEC), and non-small cell lung cancer. Additionally, we explore its expression in extra-pulmonary NEN (EP-NEN) using a standardized DLL3 IHC assay. DLL3 expression is enriched in SCLC, LCNEC along with combined histology lung cancers. Moreover, we find a wide range of DLL3 expression in high-grade EP-NEN. We describe heterogenous DLL3 expression not only in SCLC but also in different NEN types. This comprehensive characterization of DLL3 can help guide future clinical trial design targeting DLL3 in NEN including LCNEC and EP-NEN that are lacking standard of care treatment options. Competing Interests: Competing interests D.M.H. reports to be consultant for Exelixis, Harpoon Therapeutics, ITM Novartis, Crinetics, Amryt, Camarus, Alphamedix, Chimeric Therapeutics, and research funded by Genentech, Thermofisher Scientific, ITM, AAA/Novartis, Camurus, RayzeBio. L.A.B. reports consulting or Advisory Board for Merck Sharp & Dohme Corp., Arrowhead Pharmaceuticals, Chugai Pharmaceutical Co., AstraZeneca Pharmaceuticals, Genetech Inc., BeiGene, AbbVie, Jazz Pharmaceuticals, Puma Biotechnology, Amgen Inc., Daiichi Sankyo, Novartis, and research funding from AstraZeneca Pharmaceuticals, Amgen Inc., Jazz Pharmaceuticals. A.R.E. reports to be a shareholder and former employee of Amgen Inc. (© 2024. The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink